ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 253 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q4 2020. The put-call ratio across all filers is 0.32 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $86,977 | -89.7% | 15,959 | -87.4% | 0.01% | -90.6% |
| Q2 2023 | $847,762 | -10.8% | 126,343 | +17.4% | 0.12% | -9.3% |
| Q1 2023 | $950,629 | +15.6% | 107,659 | +0.0% | 0.13% | -3.0% |
| Q4 2022 | $822,393 | +116.4% | 107,643 | +101.9% | 0.13% | +129.3% |
| Q3 2022 | $380,000 | -21.6% | 53,325 | -11.0% | 0.06% | +34.9% |
| Q2 2022 | $485,000 | -42.0% | 59,893 | -0.6% | 0.04% | -40.3% |
| Q1 2022 | $836,000 | -64.7% | 60,252 | -28.5% | 0.07% | -60.0% |
| Q4 2021 | $2,365,000 | -28.9% | 84,300 | -13.9% | 0.18% | -24.7% |
| Q3 2021 | $3,327,000 | -15.0% | 97,872 | +2.2% | 0.24% | -7.7% |
| Q2 2021 | $3,915,000 | +2.9% | 95,804 | +1.4% | 0.26% | -5.1% |
| Q1 2021 | $3,805,000 | -40.9% | 94,516 | -13.3% | 0.27% | -37.2% |
| Q4 2020 | $6,443,000 | -21.1% | 108,959 | -35.1% | 0.44% | -19.3% |
| Q3 2020 | $8,170,000 | +1521.0% | 168,007 | +1513.4% | 0.54% | +1485.3% |
| Q2 2020 | $504,000 | – | 10,413 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,377,665 | $12,958,274 | 12.23% |
| Eagle Health Investments LP | 1,214,860 | $6,620,987 | 1.46% |
| Matrix Capital Management Company, LP | 11,572,590 | $63,070,616 | 0.76% |
| Aristotle Atlantic Partners, LLC | 3,058,206 | $16,667,223 | 0.67% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $163,465,709 | 0.66% |
| Pier Capital, LLC | 719,067 | $3,918,915 | 0.63% |
| DDD Partners, LLC | 783,697 | $3,385,571 | 0.49% |
| ARK Investment Management | 11,509,308 | $62,725,728 | 0.48% |
| Nikko Asset Management Americas, Inc. | 6,570,939 | $35,680,199 | 0.43% |
| Triatomic Management LP | 102,889 | $560,745 | 0.39% |